Clinical Orthopaedics and Related Research®

, Volume 472, Issue 1, pp 66–72 | Cite as

Preliminary Results Suggest Tranexamic Acid is Safe and Effective in Arthroplasty Patients with Severe Comorbidities

  • Daniel R. Whiting
  • Blake P. Gillette
  • Christopher Duncan
  • Hugh Smith
  • Mark W. Pagnano
  • Rafael J. Sierra
Symposium: 2013 Knee Society Proceedings

Abstract

Background

Tranexamic acid (TXA) reduces blood loss and transfusion after total joint arthroplasty (TJA) but concerns remain that patients with severe medical comorbidities might be at increased risk for thromboembolic complications.

Questions/purposes

Among patients undergoing primary TJA with severe systemic medical disease, (1) was TXA associated with increased symptomatic thromboembolic events; (2) was TXA associated with decreased blood transfusion rates; and (3) were there differences in symptomatic thromboembolism or transfusions in the subset of patients with a history of, or risk factors for; thromboembolic disease?

Methods

We performed a retrospective review of 1131 primary TJAs in 1002 patients with American Society of Anesthesiologists score III or IV. Of these, 402 had at least one of seven risk factors for thromboembolic events and were designated as high risk; 240 of those patients received TXA. Outcome measures included 30-day postoperative symptomatic thromboembolic events and postoperative transfusion.

Results

There were no differences in symptomatic thromboembolic events within 30 days of surgery between patients who received TXA and those who did not (2.5% versus 2.6%, p = 0.97). Fewer patients treated with TXA received transfusions (11% with versus 41% without; p < 0.0001). In high-risk patients, TXA was not associated with an increase in symptomatic thromboembolic events (6.7% with versus 4.3% without; p = 0.27) and was associated with a decrease in transfusion rates (17% with versus 48% without; p = 0.001).

Conclusions

Although TXA seemed safe and effective in this database review of patients with severe medical comorbidities, a larger prospective trial is warranted to confirm these results.

Level of Evidence

Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

Notes

Acknowledgments

We thank Robert T. Trousdale MD, for his assistance with this research and the following for their assistance in data analysis and verification: Christina Wood-Wentz MS, and Jordan Rosedahl BA, of the Division of Biomedical Statistics and Informatics as well as the staff of the Department of Transfusion Medicine.

References

  1. 1.
    Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion. 2008;48:519–525.PubMedCrossRefGoogle Scholar
  2. 2.
    Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand. 2001;72:442–448.PubMedCrossRefGoogle Scholar
  3. 3.
    Bierbaum B, Callaghan J, Galante J, Rubash H, Tooms R, Welch R. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81:2–10.PubMedGoogle Scholar
  4. 4.
    Camarasa MA, Olle G, Serra-Prat M, Martin A, Sanchez M, Ricos P, Perez A, Opisso L. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth. 2006;96:576–582.PubMedCrossRefGoogle Scholar
  5. 5.
    Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials. Transfusion. 2005;45:1302–1307.PubMedCrossRefGoogle Scholar
  6. 6.
    DailyMed [Internet]. Bethesda, MD, USA: National Library of Medicine; 2006 [updated February 26, 2013 Feb 26]. Current medication information: Cyklokapraon (tranexamic acid). Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e89a7d9-4da4-42aa-b7f8-c602c24eefe5. Accessed April 25, 2013.
  7. 7.
    Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57:1005–1032.PubMedCrossRefGoogle Scholar
  8. 8.
    Engel JM, Hohaus T, Ruwoldt R, Menges T, Jurgensen I, Hempelmann G. Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. Anesth Analg. 2001;92:775–780.PubMedCrossRefGoogle Scholar
  9. 9.
    Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010;18:132–138.PubMedGoogle Scholar
  10. 10.
    Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319–2331.PubMedCrossRefGoogle Scholar
  11. 11.
    Gill JB, Rosenstein A. The use of antifibrinolytic agents in total hip arthroplasty: a meta-analysis. J Arthroplasty. 2006;21:869–873.PubMedCrossRefGoogle Scholar
  12. 12.
    Gillette B, DeSimone L, Trousdale R, Pagnano M, Sierra R. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2013;471:150–154.PubMedCrossRefGoogle Scholar
  13. 13.
    Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;3:CD001886.Google Scholar
  14. 14.
    Hiippala ST, Strid LJ, Wennerstrand MI, V Arvela JV, Niemala HM, Mantyla SK, Kuisma RP, Ylienen JE. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg. 1997;84:839–844.PubMedGoogle Scholar
  15. 15.
    Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003;31:529–537.PubMedGoogle Scholar
  16. 16.
    Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. Br Med J. 2012; 345:e5798.CrossRefGoogle Scholar
  17. 17.
    Hynes M, Calder P, Scott G. The use of tranexamic acid to reduce blood loss during total knee arthroplasty. Knee. 2003;10:375–377.PubMedCrossRefGoogle Scholar
  18. 18.
    Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009;123:687–696.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee GC, Hawes T, Cushner FD, Scott WN. Current trends in blood conservation in total knee arthroplasty. Clin Orthop Relat Res. 2005;440:170–174.PubMedCrossRefGoogle Scholar
  20. 20.
    Lemay E, Guay J, Cote C, Roy A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement. Can J Anaesth. 2004;51:31–37.PubMedCrossRefGoogle Scholar
  21. 21.
    Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am. 2000;82:675–684.PubMedGoogle Scholar
  22. 22.
    Sehat K, Evans R, Newman J. Hidden blood loss following hip and knee arthroplasty. J Bone Joint Surg Br. 2004;86:561–565.PubMedGoogle Scholar
  23. 23.
    Shiga T, Wajima Z, Inoue T, Sakamoto A. Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials. Anesth Analg. 2005;101:1602–1607.PubMedCrossRefGoogle Scholar
  24. 24.
    Slaughter TF, Greenberg CS. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol. 1997;56:32–36.PubMedCrossRefGoogle Scholar
  25. 25.
    Veien M, Sorensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand. 2002;46:1206–1211.PubMedCrossRefGoogle Scholar
  26. 26.
    Yamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty. J Bone Joint Surg Am. 2005;87:766–770.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang Z, Chen W, Wu L. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012;94:1153–1159.PubMedGoogle Scholar
  28. 28.
    Zohar E, Fredman B, Ellis MH, Ifrach N, Stern A, Jedeikin R. A comparative study of the postoperative allogeneic blood-sparing effects of tranexamic acid and of desmopressin after total knee replacement. Transfusion. 2001;41:1285–1289.PubMedCrossRefGoogle Scholar

Copyright information

© The Association of Bone and Joint Surgeons® 2013

Authors and Affiliations

  • Daniel R. Whiting
    • 1
  • Blake P. Gillette
    • 1
  • Christopher Duncan
    • 1
  • Hugh Smith
    • 1
  • Mark W. Pagnano
    • 1
  • Rafael J. Sierra
    • 1
  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations